{"id":"https://openalex.org/W4387208945","doi":"https://doi.org/10.1007/s40801-023-00391-1","title":"Real-World Analysis of Clinical and Demographic Characteristics, Treatment Patterns, and Outcomes in Predominantly Older Patients with HR+/HER2\u2212 Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice","display_name":"Real-World Analysis of Clinical and Demographic Characteristics, Treatment Patterns, and Outcomes in Predominantly Older Patients with HR+/HER2\u2212 Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice","publication_year":2023,"publication_date":"2023-09-29","ids":{"openalex":"https://openalex.org/W4387208945","doi":"https://doi.org/10.1007/s40801-023-00391-1","pmid":"https://pubmed.ncbi.nlm.nih.gov/37775689","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/10730497"},"language":"en","primary_location":{"id":"doi:10.1007/s40801-023-00391-1","doi":"https://doi.org/10.1007/s40801-023-00391-1","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40801-023-00391-1","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40801-023-00391-1.pdf","source":{"id":"https://openalex.org/S2764379982","display_name":"Drugs - Real World Outcomes","issn_l":"2198-9788","issn":["2198-9788","2199-1154"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","norway-1","oarl","poland-20","russia-white-list-3"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drugs - Real World Outcomes","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W4387208945"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://link.springer.com/content/pdf/10.1007/s40801-023-00391-1.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5007290313","display_name":"Alistair E. Ring","orcid":"https://orcid.org/0000-0003-1230-2973","observed_orcids":["https://orcid.org/0000-0003-1230-2973"]},"institutions":[{"id":"https://openalex.org/I1325846038","display_name":"Royal Marsden NHS Foundation Trust","ror":"https://ror.org/0008wzh48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038"]},{"id":"https://openalex.org/I4210121186","display_name":"Royal Marsden Hospital","ror":"https://ror.org/034vb5t35","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038","https://openalex.org/I4210121186"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Alistair Ring","raw_affiliation_strings":["The Royal Marsden Hospital NHS Foundation Trust, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Royal Marsden Hospital NHS Foundation Trust, London, UK","institution_ids":["https://openalex.org/I1325846038","https://openalex.org/I4210121186"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009694312","display_name":"Meghan Sri Karuturi","orcid":"https://orcid.org/0000-0001-8795-3901","observed_orcids":["https://orcid.org/0000-0001-8795-3901"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Meghan Karuturi","raw_affiliation_strings":["MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005185722","display_name":"Emily Nash Smyth","orcid":"https://orcid.org/0000-0003-0583-0882","observed_orcids":["https://orcid.org/0000-0003-0583-0882"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Emily Nash Smyth","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, IN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026174766","display_name":"Tasneem Lokhandwala","orcid":"https://orcid.org/0000-0002-1983-9557","observed_orcids":["https://orcid.org/0000-0002-1983-9557"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Tasneem Lokhandwala","raw_affiliation_strings":["Xcenda, LLC, 5025 Plano Parkway, Carrollton, TX, 75010, USA. Tasneem.Lokhandwala@xcenda.com","Xcenda, LLC, 5025 Plano Parkway, Carrollton, TX, 75010, USA"],"raw_orcid":"https://orcid.org/0000-0002-1983-9557","affiliations":[{"raw_affiliation_string":"Xcenda, LLC, 5025 Plano Parkway, Carrollton, TX, 75010, USA. Tasneem.Lokhandwala@xcenda.com","institution_ids":[]},{"raw_affiliation_string":"Xcenda, LLC, 5025 Plano Parkway, Carrollton, TX, 75010, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043605449","display_name":"Kristin M. Sheffield","orcid":"https://orcid.org/0000-0003-3940-1795","observed_orcids":["https://orcid.org/0000-0003-3940-1795"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kristin M. Sheffield","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, IN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Joanne Willey","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Joanne Willey","raw_affiliation_strings":["Xcenda, LLC, 5025 Plano Parkway, Carrollton, TX, 75010, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Xcenda, LLC, 5025 Plano Parkway, Carrollton, TX, 75010, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108143901","display_name":"Orsolya Lunacsek","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Orsolya Lunacsek","raw_affiliation_strings":["Xcenda, LLC, 5025 Plano Parkway, Carrollton, TX, 75010, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Xcenda, LLC, 5025 Plano Parkway, Carrollton, TX, 75010, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028712710","display_name":"Francisco J. Sapunar","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Francisco Sapunar","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, IN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086108457","display_name":"Zhanglin Lin Cui","orcid":"https://orcid.org/0000-0002-7034-0946","observed_orcids":["https://orcid.org/0000-0002-7034-0946"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Zhanglin Lin Cui","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, IN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047612420","display_name":"Anna D\u2019Souza Coutinho","orcid":"https://orcid.org/0009-0004-7633-6894","observed_orcids":["https://orcid.org/0009-0004-7633-6894"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anna D. Coutinho","raw_affiliation_strings":["Xcenda, LLC, 5025 Plano Parkway, Carrollton, TX, 75010, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Xcenda, LLC, 5025 Plano Parkway, Carrollton, TX, 75010, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5083092373","display_name":"Sarah Rybowski","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sarah Rybowski","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, IN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I168537998"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5026174766"],"corresponding_institution_ids":[],"apc_list":{"value":2690,"currency":"USD","value_usd":2690},"apc_paid":{"value":2690,"currency":"USD","value_usd":2690},"fwci":0.6016,"has_fulltext":true,"cited_by_count":5,"citation_normalized_percentile":{"value":0.63531483,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":96},"biblio":{"volume":"10","issue":"4","first_page":"589","last_page":"603"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/abemaciclib","display_name":"abemaciclib","score":0.8939999938011169},{"id":"https://openalex.org/keywords/hr-her2-metastatic-breast-cancer","display_name":"HR+/HER2- metastatic breast cancer","score":0.9769999980926514},{"id":"https://openalex.org/keywords/elderly-patients","display_name":"elderly patients","score":0.8040000200271606},{"id":"https://openalex.org/keywords/cdk4-6-inhibitors","display_name":"CDK4/6 inhibitors","score":0.9179999828338623},{"id":"https://openalex.org/keywords/real-world-outcomes","display_name":"real-world outcomes","score":0.7269999980926514},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.859000027179718},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.765999972820282},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.8460000157356262},{"id":"https://openalex.org/keywords/endocrine-therapy","display_name":"endocrine therapy","score":0.7379999756813049},{"id":"https://openalex.org/keywords/community-oncology","display_name":"community oncology","score":0.800000011920929},{"id":"https://openalex.org/keywords/treatment-patterns","display_name":"treatment patterns","score":0.6159999966621399},{"id":"https://openalex.org/keywords/clinical-benefit-rate","display_name":"clinical benefit rate","score":0.6819999814033508},{"id":"https://openalex.org/keywords/age-as-prognostic-factor","display_name":"age as prognostic factor","score":0.6330000162124634},{"id":"https://openalex.org/keywords/time-to-treatment-discontinuation","display_name":"time to treatment discontinuation","score":0.6240000128746033},{"id":"https://openalex.org/keywords/time-to-chemotherapy","display_name":"time to chemotherapy","score":0.7089999914169312},{"id":"https://openalex.org/keywords/stable-disease","display_name":"stable disease","score":0.5600000023841858},{"id":"https://openalex.org/keywords/visceral-disease","display_name":"visceral disease","score":0.5609999895095825}],"concepts":[{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.7783660888671875},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.710434079170227},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.6357855200767517},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6243234872817993},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5979259014129639},{"id":"https://openalex.org/C2779974597","wikidata":"https://www.wikidata.org/wiki/Q28448986","display_name":"Clinical Practice","level":2,"score":0.5679911375045776},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5575262904167175},{"id":"https://openalex.org/C512399662","wikidata":"https://www.wikidata.org/wiki/Q3505712","display_name":"Family medicine","level":1,"score":0.1065240204334259}],"mesh":[],"locations_count":4,"locations":[{"id":"doi:10.1007/s40801-023-00391-1","doi":"https://doi.org/10.1007/s40801-023-00391-1","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40801-023-00391-1","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40801-023-00391-1.pdf","source":{"id":"https://openalex.org/S2764379982","display_name":"Drugs - Real World Outcomes","issn_l":"2198-9788","issn":["2198-9788","2199-1154"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","norway-1","oarl","poland-20","russia-white-list-3"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drugs - Real World Outcomes","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:10730497","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/10730497","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10730497/pdf/40801_2023_Article_391.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drugs Real World Outcomes","raw_type":"Text"},{"id":"pmid:37775689","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/37775689","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drugs - real world outcomes","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:aa1788c9bb694e03a3c95d560933648e","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/aa1788c9bb694e03a3c95d560933648e","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Drugs - Real World Outcomes, Vol 10, Iss 4, Pp 589-603 (2023)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1007/s40801-023-00391-1","doi":"https://doi.org/10.1007/s40801-023-00391-1","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40801-023-00391-1","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40801-023-00391-1.pdf","source":{"id":"https://openalex.org/S2764379982","display_name":"Drugs - Real World Outcomes","issn_l":"2198-9788","issn":["2198-9788","2199-1154"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","norway-1","oarl","poland-20","russia-white-list-3"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drugs - Real World Outcomes","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4387208945.pdf","grobid_xml":"https://content.openalex.org/works/W4387208945.grobid-xml"},"referenced_works_count":48,"referenced_works":["https://openalex.org/W165173872","https://openalex.org/W1971185870","https://openalex.org/W1975879668","https://openalex.org/W2070780645","https://openalex.org/W2112646145","https://openalex.org/W2116144791","https://openalex.org/W2140056658","https://openalex.org/W2159427817","https://openalex.org/W2162383121","https://openalex.org/W2165999332","https://openalex.org/W2166463482","https://openalex.org/W2204808283","https://openalex.org/W2263556989","https://openalex.org/W2290950904","https://openalex.org/W2552099557","https://openalex.org/W2560635244","https://openalex.org/W2614466076","https://openalex.org/W2617437931","https://openalex.org/W2620993107","https://openalex.org/W2763875663","https://openalex.org/W2788603587","https://openalex.org/W2802776309","https://openalex.org/W2804105316","https://openalex.org/W2805575723","https://openalex.org/W2901884329","https://openalex.org/W2910972034","https://openalex.org/W2950839322","https://openalex.org/W2975749949","https://openalex.org/W2976415870","https://openalex.org/W2977565884","https://openalex.org/W2982150569","https://openalex.org/W3027235130","https://openalex.org/W3028148690","https://openalex.org/W3030172639","https://openalex.org/W3049370161","https://openalex.org/W3087561595","https://openalex.org/W3091199432","https://openalex.org/W3091902443","https://openalex.org/W3115380088","https://openalex.org/W3120214437","https://openalex.org/W3132856650","https://openalex.org/W3157645496","https://openalex.org/W3161555469","https://openalex.org/W3207557929","https://openalex.org/W4206666777","https://openalex.org/W4206841660","https://openalex.org/W4234749243","https://openalex.org/W4295509263"],"related_works":["https://openalex.org/W4396871680","https://openalex.org/W4414166908","https://openalex.org/W3013014737","https://openalex.org/W3132856650","https://openalex.org/W4416266688","https://openalex.org/W4295509263","https://openalex.org/W4412522450","https://openalex.org/W4377289713","https://openalex.org/W3161555469","https://openalex.org/W4411290496"],"abstract_inverted_index":{"INTRODUCTION:":[0],"Hormone":[1],"receptor-positive":[2],"(HR+)/human":[3],"epidermal":[4],"growth":[5],"factor":[6],"receptor":[7],"2-negative":[8],"(HER2-)":[9],"is":[10,60],"the":[11,54,78,156,165,238,341,367],"most":[12,190,230],"frequently":[13],"diagnosed":[14],"metastatic":[15],"breast":[16],"cancer":[17],"(mBC)":[18],"subtype.":[19],"Combinations":[20],"of":[21,43,63,83,176,187,197,204,214,278,321],"endocrine":[22],"therapy":[23,215],"(ET)":[24],"with":[25,36,47,86,104,134,172,243,287,344,379],"cyclin-dependent":[26],"kinase":[27],"4/6":[28],"inhibitors":[29],"(CDK4":[30],"&":[31,223,353],"6is)":[32],"improve":[33],"outcomes":[34,124],"compared":[35],"ET":[37],"alone.":[38],"The":[39,235,248,265,275],"efficacy":[40],"and":[41,111,120,122,129,147,161,184,226,348,351],"safety":[42],"abemaciclib":[44,90,193,279],"among":[45,132],"patients":[46,85,133,322,335,378],"HR+/HER2-":[48,87],"mBC":[49,88,198,217],"has":[50],"been":[51],"demonstrated":[52],"in":[53,67,91,340,361,376],"MONARCH":[55,342],"clinical":[56,108],"trials;":[57],"however,":[58],"there":[59],"a":[61,173,202,325],"paucity":[62],"real-world":[64,123,363],"evidence,":[65],"particularly":[66,375],"older":[68,337,377],"patients.":[69],"METHODS":[70],"AND":[71],"MATERIALS:":[72],"This":[73],"retrospective":[74],"cohort":[75],"study":[76],"analyzed":[77],"electronic":[79],"medical":[80],"record":[81],"data/charts":[82],"adult":[84],"receiving":[89],"US-based":[92],"community":[93],"oncology":[94],"settings":[95],"(1":[96],"September":[97,101],"2017":[98],"to":[99,139,143,281,331,372],"30":[100],"2019).":[102],"Patients":[103,200],"other":[105,221],"primary":[106],"malignancies,":[107],"trial":[109],"enrollment,":[110],"incomplete":[112],"charts":[113],"were":[114,151,170,180,336,358],"excluded.":[115],"Patient":[116],"characteristics,":[117],"treatment":[118,144],"attributes":[119],"patterns,":[121],"(clinical":[125],"benefit":[126],"rate":[127,277],"[CBR]":[128],"stable":[130,246],"disease":[131],"response":[135],"data":[136],"available,":[137],"time":[138,142],"chemotherapy":[140,228,350],"[TTC],":[141],"discontinuation":[145,276],"[TTD],":[146],"progression-free":[148],"survival":[149],"[PFS])":[150],"summarized.":[152],"Multivariable":[153],"models":[154],"evaluated":[155],"association":[157],"between":[158],"demographic/clinical":[159],"characteristics":[160],"outcomes.":[162],"RESULTS:":[163],"Of":[164],"448":[166],"final":[167],"patients,":[168],"99%":[169],"female,":[171],"median":[174,185,203,249,254,266],"age":[175,288],"67":[177],"years":[178,196],"(25%":[179],"\u2265":[181,313],"75":[182],"years)":[183],"follow-up":[186],"11":[188],"months;":[189],"(60%)":[191],"initiated":[192],"within":[194],"2":[195],"diagnosis.":[199],"received":[201],"1":[205],"(P25":[206],"=":[207,210,291,295,300,305,310,316],"0,":[208],"P75":[209],"3)":[211],"prior":[212,227,330,349],"line":[213],"for":[216,237,369],"before":[218],"abemaciclib,":[219],"including":[220],"CDK4":[222,352],"6is":[224],"(48%)":[225],"(31%);":[229],"(57%)":[231],"had":[232,324],"visceral":[233,346],"disease.":[234,247],"CBR":[236],"overall":[239,323],"population":[240],"was":[241,251,256,268],"53%,":[242],"48%":[244],"achieving":[245],"TTC":[250],"not":[252],"reached;":[253],"TTD":[255],"249":[257],"days":[258,270],"(95%":[259,271],"confidence":[260],"interval":[261],"[CI]:":[262],"202,":[263],"304).":[264],"PFS":[267],"329":[269],"CI":[272],"266,":[273],"386).":[274],"owing":[280],"adverse":[282],"events":[283],"(30%)":[284],"trended":[285],"higher":[286,359],"(years)":[289],"(P":[290],"0.027):":[292],"18-49":[293],"(n":[294,299,304,309,315],"42;":[296],"19%),":[297],"50-64":[298],"155;":[301],"25%),":[302],"65-74":[303],"138;":[306],"32%),":[307],"75-84":[308],"82;":[311],"37%),":[312],"85":[314],"31;":[317],"49%);":[318],"only":[319],"23%":[320],"dose":[326],"hold":[327],"or":[328],"reduction":[329],"discontinuation.":[332],"CONCLUSIONS:":[333],"These":[334],"than":[338,360],"those":[339],"studies":[343,364],"substantial":[345],"disease,":[347],"6i":[354],"use.":[355],"Discontinuation":[356],"rates":[357],"previous":[362],"(11.9%),":[365],"highlighting":[366],"need":[368],"proactive":[370],"management":[371],"optimize":[373],"outcomes,":[374],"mBC.":[380]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":1}],"updated_date":"2026-10-29T09:56:32.521200","created_date":"2023-09-30T00:00:00"}